medwireNews: A Clinical Practice Guideline for the management of non-oncogene addicted metastatic non-small-cell lung cancer (NSCLC) has been issued by ESMO.
The guideline covers a range of topics, of which diagnosis, staging and risk assessment, and follow-up and survivorship are discussed in the supplementary material, with the bulk of the main article focusing on treatment.
The options for treatment vary depending on whether patients do or do not have contraindications for immunotherapy (details available in the ESMO Clinical Practice Guideline for managing toxicities of immunotherapy), and also take into account factors such as histology, PD-L1 expression levels, performance status and comorbidities.
The authors also provide guidance for treating special populations, such as older patients and those with oligometastases.
The recommendations – which are published in the Annals of Oncology – are based on available evidence and “the authors’ collective expert opinion.” The guideline was created in accordance with the ESMO standard operating procedures.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2023 Springer Healthcare Ltd, part of the Springer Nature Group